$CI earnings report

The Cigna Group Reports Strong Third Quarter 2026 Results, Raises 2026 Outlook. AlphAI read Cigna Group's third quarter 2026 filing as solid. 2 quarters are on record below.

third quarter 2026

AlphAI · Earnings readCI · third quarter 2026 · ended September 30, 2026

The Cigna Group Reports Strong Third Quarter 2026 Results, Raises 2026 Outlook

✓Solid quarter

Total revenues increased 6% to $73.7 billion and adjusted income from operations per share increased to $7.98, while GAAP shareholders’ net income declined from the absence of an after-tax gain on sale recognized in third quarter 2025. Cigna Healthcare expanded revenue and pre-tax adjusted income from operations, offsetting a decline in Pharmacy Benefit Services pre-tax adjusted income from operations.

Revenue
$73.7B
6 % y/y
Evernorth Health Services
$ 63,774 million adjusted revenues
6 % y/y
EPS · non-GAAP
$ 7.98

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Total revenues, three months ended September 30, 2026GAAP$73.68B–6 %
Pharmacy revenues, three months ended September 30, 2026GAAP$58.98B––
Premiums, three months ended September 30, 2026GAAP$9.88B––
Fees and other revenues, three months ended September 30, 2026GAAP$4.53B––
Net investment income, three months ended September 30, 2026GAAP$287M––
Net investment results from certain equity method investments, three months ended September 30, 2026other$110M––
Adjusted revenues, three months ended September 30, 2026non-GAAP$73.79B––
Shareholders’ net income, three months ended September 30, 2026GAAP$1.44B––
Adjusted income from operations, three months ended September 30, 2026non-GAAP$2.10B–stable
Shareholders’ net income per diluted share, three months ended September 30, 2026GAAP$ 5.47––
Adjusted income from operations per diluted share, three months ended September 30, 2026non-GAAP$ 7.98––
SG&A expense ratio, third quarter 2026GAAP4.9%––
Adjusted SG&A expense ratio, third quarter 2026non-GAAP4.7%––
Enterprise selling, general and administrative expenses, third quarter 2026GAAP$3.61B––
Enterprise selling, general and administrative expenses excluding special items, third quarter 2026non-GAAP$3.44B––
Special items excluded from adjusted SG&A expense ratio, third quarter 2026non-GAAP$169M––
Total revenues, nine months ended September 30, 2026GAAP$213.8B––
Pharmacy revenues, nine months ended September 30, 2026GAAP$170.2B––
Premiums, nine months ended September 30, 2026GAAP$29.56B––
Fees and other revenues, nine months ended September 30, 2026GAAP$13.34B––
Net investment income, nine months ended September 30, 2026GAAP$761M––
Net investment results from certain equity method investments, nine months ended September 30, 2026other$23M––
Adjusted revenues, nine months ended September 30, 2026non-GAAP$213.9B––
Shareholders’ net income, nine months ended September 30, 2026GAAP$4.76B––
Adjusted income from operations, nine months ended September 30, 2026non-GAAP$6.22B––
Shareholders’ net income per diluted share, nine months ended September 30, 2026GAAP$ 18.02––
Adjusted income from operations per diluted share, nine months ended September 30, 2026non-GAAP$ 23.55––
Weighted average shares, three months ended September 30, 2026other263.8M––
Weighted average shares, nine months ended September 30, 2026other263.9M––
Total pharmacy customers, September 30, 2026other117.7M––
U.S. Healthcare customers, September 30, 2026other16.70M––
International Health customers, September 30, 2026other1.75M––
Total medical customers, September 30, 2026other18.45M––
Behavioral Care customers, September 30, 2026other23.01M––
Dental customers, September 30, 2026other18.4M––
Total customer relationships, September 30, 2026other177.6M––
Cigna Healthcare medical care ratio, third quarter 2026other85.0%––
Cigna Healthcare net medical costs payable, September 30, 2026other$4.86B––
Gross medical costs payable, September 30, 2026other$4.99B––
Favorable prior year reserve development on a gross pre-tax basis, nine months ended September 30, 2026other$356M––
Shareholders’ equity, September 30, 2026GAAP$43.38B––
Shareholders’ equity per share, September 30, 2026GAAP$ 164.70––

Segments

SegmentRevenueq/qy/y
Evernorth Health ServicesGrowth reflected Pharmacy Benefit Services adjusted-revenue growth primarily due to drug mix, while Specialty and Care Services reflected strong specialty distribution revenue growth, partially offset by lower specialty pharmacy revenue from higher biosimilar and specialty generic adoption.$ 63,774 million adjusted revenues–6 %
Pharmacy Benefit ServicesAdjusted-revenue growth was primarily due to drug mix. Pre-tax adjusted income from operations decreased 22%, primarily reflecting large client contract renewals and strategic investments.$ 37,276 million adjusted revenues–9 %
Specialty and Care ServicesStrong specialty distribution revenue growth was partly offset by lower specialty pharmacy revenue, reflecting higher biosimilar and specialty generic adoption.$ 26,498 million adjusted revenues–1 %
Cigna HealthcareGrowth primarily reflected premium rate increases to cover expected increases in medical costs.$ 11,708 million adjusted revenues–9%

full year ending December 31, 2026 outlook

  • NoteAdjusted income from operations, per share: at least $30.60
  • Note+ $0.15 change from prior projection
  • NoteEvernorth adjusted income from operations, pre-tax: at least $6,900 million
  • NoteCigna Healthcare adjusted income from operations, pre-tax: at least $4,600 million
  • Note+ $50 million change from prior projection
  • NoteCigna Healthcare Medical Care Ratio: 84.2% +/- 25 bps
  • NoteCigna Healthcare Medical Care Ratio: Narrowed by 50 bps

Capital returns

  • Year to date through November 4, 2026, the Company repurchased 1.8 million shares of common stock for approximately $500 million.
  • The outlook includes the impact of expected future share repurchases and anticipated 2026 dividends.

What drove it

  • Total revenues increased 6% relative to third quarter 2025, driven by growth in both Evernorth Health Services and Cigna Healthcare.
  • Cigna Healthcare pre-tax adjusted income from operations increased 15%, primarily due to higher net investment income and improved operating efficiency.
  • Specialty and Care Services pre-tax adjusted income from operations increased 15%, primarily reflecting strong organic growth in specialty businesses, including higher biosimilar and specialty generic adoption.
  • Total medical customers increased 2% from December 31, 2025 to 18.5 million, reflecting growth in Middle and Select markets, partially offset by lower membership in National Accounts.

Concerns

  • Pharmacy Benefit Services pre-tax adjusted income from operations decreased 22%, primarily reflecting large client contract renewals and strategic investments.
  • Total customer relationships at September 30, 2026 decreased 6% from December 31, 2025 to 177.6 million, due to lower pharmacy and behavioral customers.
  • Total behavioral customers decreased 19% from December 31, 2025 to 23 million due to the termination of a government contract, with minimal impact to revenues and adjusted income from operations.
  • The Cigna Healthcare MCR was 85.0% for third quarter 2026, compared to 84.8% for third quarter 2025, primarily due to U.S. Employer business mix.
  • The Company announced its planned exit from the Individual and Family Plans medical business as of January 1, 2027.

What to watch

  • Delivery of at least $30.60 of full-year 2026 adjusted income from operations per share.
  • Evernorth adjusted income from operations, pre-tax outlook of at least $6,900 million.
  • Cigna Healthcare adjusted income from operations, pre-tax outlook of at least $4,600 million and Medical Care Ratio outlook of 84.2% +/- 25 bps.
  • Execution of the “Accelerate to One” multi-year $3B modernization and productivity initiative.
  • Pharmacy Benefit Services contract renewals, strategic investments, and customer transitions.

Balance sheet and cash flow

  • The debt-to-capitalization ratio was 41.8% at September 30, 2026 compared to 44.9% at September 30, 2025 and 43.0% at December 31, 2025.
  • Common shares outstanding were 263,403 thousand at September 30, 2026, compared with 267,072 thousand at September 30, 2025 and 264,154 thousand at June 30, 2026.
  • Shareholders’ equity at September 30, 2026 was $ 43,383 million, compared with $ 41,805 million at September 30, 2025.
  • Shareholders’ equity per share at September 30, 2026 was $ 164.70, compared with $ 156.53 at September 30, 2025.

Analysis

The Cigna Group reported third-quarter total revenues of $73,683 million, compared with $69,748 million in third quarter 2025, and adjusted revenues of $73,793 million, compared with $69,570 million. Revenue growth was supported by both operating segments. Evernorth Health Services adjusted revenues were $63,774 million, while Cigna Healthcare adjusted revenues were $11,708 million. Cigna Healthcare growth primarily reflected premium rate increases to cover expected increases in medical costs.

GAAP shareholders’ net income was $1,442 million, or $5.47 per share, compared with $1,868 million, or $6.98 per share. The release attributes the decline primarily to the absence of an after-tax gain on sale recognized in third quarter 2025. Underlying profitability was steadier: adjusted income from operations was $2,104 million, compared with $2,096 million, and adjusted income from operations per share was $7.98, compared with $7.83.

Segment mix was uneven. Evernorth pre-tax adjusted income from operations was $1,829 million, compared with $1,903 million, as Pharmacy Benefit Services declined 22% to $765 million, primarily reflecting large client contract renewals and strategic investments. Specialty and Care Services offset part of this pressure, with pre-tax adjusted income from operations of $1,064 million, up 15%, on strong organic growth in specialty businesses. Cigna Healthcare pre-tax adjusted income from operations rose 15% to $1,193 million, attributed to higher net investment income and improved operating efficiency.

Membership trends warrant attention. Total customer relationships were 177,562 thousand at September 30, 2026, versus 182,765 thousand at December 31, 2025. Pharmacy customers declined 5% from December 31, 2025 amid expected client transitions and lower health-plan-client membership, and behavioral customers declined 19% following termination of a government contract. Medical customers increased 2% from December 31, 2025 to 18.5 million. The Cigna Healthcare MCR was 85.0%, compared with 84.8% in third quarter 2025.

Capital deployment included repurchases of 1.8 million common shares for approximately $500 million through November 4, 2026. The debt-to-capitalization ratio was 41.8% at September 30, 2026, compared with 44.9% one year earlier. Management raised full-year 2026 adjusted income from operations per-share outlook to at least $30.60, a +$0.15 change from the prior projection, and raised Cigna Healthcare pre-tax adjusted income from operations outlook by +$50 million to at least $4,600 million. The company also narrowed its Cigna Healthcare Medical Care Ratio outlook by 50 bps to 84.2% +/- 25 bps.

Management, verbatim

Our vision for The Cigna Group’s next chapter of profitable growth is grounded in delivering greater value and personalized experiences for our customers, with three priorities : driving core growth, leveraging our distinct capabilities, and executing with discipline.

Brian Evanko, President and Chief Executive Officer of The Cigna Group

As we put our strategy in action, our strong third quarter results demonstrate how we are building on this momentum by making health care more affordable and personalized, while advancing Accelerate to One to drive productivity, reduce costs, and support sustained long-term earnings growth.

Brian Evanko, President and Chief Executive Officer of The Cigna Group

Not in the filing

stated, not guessed
  • Operating income on a GAAP basis was not reported.
  • Gross profit and gross margin were not reported.
  • Operating cash flow was not reported.
  • Free cash flow was not reported.
  • Cash and cash equivalents were not reported.
  • Total debt was not reported.
  • Dividend amount was not reported.
  • A GAAP tax rate was not reported.
  • The previous outlook covered the full year 2026 only, so there is nothing to compare for this quarter.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

second quarter 2026

AlphAI · Earnings readCI · second quarter 2026 · ended June 30, 2026

The Cigna Group Reports Strong Second Quarter 2026 Results, Raises 2026 Outlook

✓Solid quarter

Total revenues increased 7% and adjusted income from operations increased 6% from second quarter 2025, while the company raised its full-year adjusted income from operations outlook to at least $30.45 per share. Cigna Healthcare earnings growth offset a decline in Evernorth pre-tax adjusted income from operations.

Revenue
$71.7B
7% y/y
Evernorth Health Services
$61.5B
increased 6% y/y
EPS · non-GAAP
$7.78

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Total RevenuesGAAP$71.67B–7%
Net Investment Results from Equity Method Investmentsother−$110M––
Adjusted Revenuesnon-GAAP$71.56B––
Shareholders' Net IncomeGAAP$1.66B––
Shareholders' Net Income, per shareGAAP$6.29 per share––
Adjusted Income from Operationsnon-GAAP$2.05B–6%
Adjusted Income from Operations, per sharenon-GAAP$7.78 per share––
Net Investment (Gains)other−$55M––
Amortization of Acquired Intangible Assetsother$296M––
Special Itemsother$153M––
SG&A expense ratioGAAP4.8%––
Adjusted SG&A expense rationon-GAAP4.6%––
Evernorth Health Services Adjusted Income from Operations, Pre-Taxnon-GAAP$1.66B–decreased 2%
Evernorth Health Services Margin, Pre-Taxnon-GAAP2.7%––
Pharmacy Benefit Services Adjusted Income from Operations, Pre-Taxnon-GAAP$609M–decreased 27%
Specialty and Care Services Adjusted Income from Operations, Pre-Taxnon-GAAP$1.05B–increased 22%
Cigna Healthcare Adjusted Income from Operations, Pre-Taxnon-GAAP$1.28B–increased 17%
Cigna Healthcare Margin, Pre-Taxnon-GAAP10.9%––
Cigna Healthcare Medical Care RatioGAAP84.5%––
Corporate and Other Operations Adjusted (Loss) from Operations, Pre-Taxnon-GAAP−$389M––
Six Months Ended June 30, 2026 Total RevenuesGAAP$140.2B––
Six Months Ended June 30, 2026 Adjusted Revenuesnon-GAAP$140.1B––
Six Months Ended June 30, 2026 Shareholders' Net IncomeGAAP$3.31B––
Six Months Ended June 30, 2026 Adjusted Income from Operationsnon-GAAP$4.11B––
Six Months Ended June 30, 2026 Shareholders' Net Income, per shareGAAP$12.55 per share––
Six Months Ended June 30, 2026 Adjusted Income from Operations, per sharenon-GAAP$15.58 per share––
Total Pharmacy Customersother118.2M––
U.S. Healthcare Customersother16.68M––
International Health Customersother1.74M––
Total Medical Customersother18.41M––
Behavioral Care Customersother27.62M––
Dental Customersother18.49M––
Total Customer Relationshipsother182.8M––

Segments

SegmentRevenueq/qy/y
Evernorth Health ServicesAdjusted revenue growth was driven by Pharmacy Benefit Services drug mix and Specialty and Care Services strong specialty volume growth.$61.47B–increased 6%
Pharmacy Benefit ServicesAdjusted revenues increased primarily due to drug mix.$34.50B–increased 8%
Specialty and Care ServicesAdjusted revenues increased reflecting strong specialty volume growth.$26.97B–increased 4%
Cigna HealthcareAdjusted revenue growth primarily reflected premium rate increases to cover expected increases in medical costs.$11.73B–increased 9%

Full Year Ending December 31, 2026 outlook

  • NoteAdjusted Income from Operations, per share: at least $30.45
  • NoteEvernorth Adjusted Income from Operations, Pre-Tax: at least $6,900 million
  • NoteCigna Healthcare Adjusted Income from Operations, Pre-Tax: at least $4,550 million
  • NoteCigna Healthcare Medical Care Ratio: 83.7% to 84.7%
  • NoteAdjusted Income from Operations, per share Change from Prior Projection: +$0.10
  • NoteCigna Healthcare Adjusted Income from Operations, Pre-Tax Change from Prior Projection: +$25 million

Capital returns

  • Year to date through July 29, 2026, the company repurchased 0.9 million shares of common stock for approximately $250 million.
  • The full-year 2026 adjusted income from operations outlook includes the impact of expected future share repurchases and anticipated 2026 dividends.

What drove it

  • Total revenues for second quarter 2026 increased 7% relative to second quarter 2025, driven by growth in both Evernorth Health Services and Cigna Healthcare.
  • Consolidated adjusted income from operations increased 6% relative to second quarter 2025, driven by higher contributions from Cigna Healthcare.
  • Cigna Healthcare adjusted income from operations, pre-tax increased 17%, primarily due to an improved margin within the U.S. Employer business.
  • Specialty and Care Services adjusted income from operations, pre-tax increased 22%, primarily reflecting strong organic growth in specialty businesses, higher generic and biosimilar adoption, and operating efficiencies.
  • The SG&A expense ratio and adjusted SG&A expense ratio primarily reflected operating efficiency.

Concerns

  • Evernorth Health Services adjusted income from operations, pre-tax decreased 2% relative to second quarter 2025.
  • Pharmacy Benefit Services adjusted income from operations, pre-tax decreased 27%, primarily reflecting client-focused initiatives, including large client contract renewals, and customer-focused initiatives.
  • Total customer relationships at June 30, 2026 decreased 3% from December 31, 2025 to 182.8 million.
  • Total pharmacy customers at June 30, 2026 decreased 4% from December 31, 2025 to 118.2 million, reflecting expected client transitions and lower membership from health plan clients.
  • The company announced its planned exit from the Individual and Family Plans medical business as of January 1, 2027.

What to watch

  • Execution against the full-year 2026 adjusted income from operations outlook of at least $30.45 per share.
  • Whether Cigna Healthcare Medical Care Ratio remains within the 83.7% to 84.7% full-year outlook range.
  • Pharmacy Benefit Services profitability following large client contract renewals and customer-focused initiatives.
  • Specialty volume growth, generic and biosimilar adoption, and associated operating efficiencies.
  • Customer transitions, health plan client membership, and the planned January 1, 2027 exit from the Individual and Family Plans medical business.

Balance sheet and cash flow

  • Cigna Healthcare net medical costs payable was $5.09 billion at June 30, 2026, $4.78 billion at March 31, 2026, and $4.49 billion at June 30, 2025.
  • Favorable prior year reserve development on a gross pre-tax basis was $268 million for the six months ended June 30, 2026 and $297 million for the six months ended June 30, 2025.

Analysis

The Cigna Group reported a solid second quarter, with total revenues of $71,668 million, up 7% from second quarter 2025, and shareholders' net income of $1,660 million, or $6.29 per share. Adjusted income from operations was $2,054 million, or $7.78 per share, up 6% from the prior-year quarter. Consolidated adjusted revenue was $71,558 million, and the SG&A expense ratio and adjusted SG&A expense ratio improved to 4.8% and 4.6%, respectively, from 5.1% and 4.9%.

Cigna Healthcare was the primary earnings contributor. Its adjusted revenues increased 9% to $11,728 million, primarily reflecting premium rate increases to cover expected increases in medical costs. Pre-tax adjusted income from operations rose 17% to $1,276 million, primarily due to improved margin in the U.S. Employer business. The segment's medical care ratio was 84.5%, compared with 83.2% in second quarter 2025, with the comparison primarily reflecting higher prior-year risk adjustment benefits in the Individual and Family Plans business recognized in second quarter 2025.

Evernorth Health Services produced adjusted revenues of $61,468 million, up 6%, but pre-tax adjusted income from operations declined 2% to $1,663 million. Pharmacy Benefit Services revenue increased 8% on drug mix, while its pre-tax adjusted income from operations declined 27% due primarily to client-focused initiatives, including large client contract renewals, and customer-focused initiatives. Specialty and Care Services revenue increased 4% on strong specialty volume growth and pre-tax adjusted income from operations rose 22%, supported by organic specialty growth, generic and biosimilar adoption, and operating efficiencies.

Customer trends were mixed. Total customer relationships at June 30, 2026 decreased 3% from December 31, 2025 to 182.8 million, while total pharmacy customers declined 4% to 118.2 million amid expected client transitions and lower membership from health plan clients. Total medical customers increased 2% from December 31, 2025 to 18.4 million, reflecting Middle and Select market growth that was partly offset by lower National Accounts membership. The company also disclosed its planned exit from the Individual and Family Plans medical business as of January 1, 2027.

Capital allocation included repurchases of 0.9 million shares for approximately $250 million year to date through July 29, 2026. Management raised full-year 2026 adjusted income from operations guidance to at least $30.45 per share, a +$0.10 change from the prior projection. The outlook also calls for at least $6,900 million of Evernorth pre-tax adjusted income from operations, at least $4,550 million for Cigna Healthcare, and a Cigna Healthcare medical care ratio of 83.7% to 84.7%.

Management, verbatim

By harnessing technology, data and AI to deliver more personalized experiences, improve access and lower costs, we are creating greater value every day. Our strong second quarter results reflect continued progress against these priorities and demonstrate the effectiveness of our strategy and execution.

Brian C. Evanko, President and Chief Executive Officer of The Cigna Group

Not in the filing

stated, not guessed
  • GAAP gross profit and gross margin
  • GAAP operating income and operating margin
  • Operating cash flow
  • Free cash flow
  • Cash and cash equivalents
  • Total debt
  • Dividend amount or dividend per share
  • Full-year 2026 revenue guidance
  • Full-year 2026 gross-margin guidance
  • Full-year 2026 operating-expense guidance
  • Full-year 2026 tax-rate guidance
  • Prior outlook release for comparison with reported results
  • Percentage changes for adjusted revenues and several reported metric line items where no change was printed
  • Prior-year comparative amounts for the six months ended June 30, 2026 metrics

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about CI earnings dates

When is Cigna Group's next earnings date?
AlphAI has no date for CI yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.